Page 12 - Bharat Biotech

Top headlines: SC orders compensation for Covid dead, discoms get help

Business Standard brings you the top news of the evening

Bharat Biotech says regulatory steps taken for Brazil vaccine contract

Bharat Biotech said it followed a "step-by-step" approach for the regulatory approval and supply contract of its Covid vaccine in Brazil, and it has not received advance payments

Blurred picture

The sharp cuts in vaccine supply projections are baffling

Bolsonaro linked to alleged corruption in buying of Bharat Bio's vaccine

Brazil senate probing the president's handling of the pandemic; country signed a contract with the Indian firm to purchase 20 million doses for $325 million.

Bolsonaro says Brazil didn't spend cent on Bharat Bio vax deal under probe

Brazil officials are investigating the deal with the Indian company, citing the fact that the government struck a speedy agreement and ignored offers from Pfizer in 2020.

A jab at veracity

States should not aim to artificially push vaccination numbers

Brazil probes Health Ministry deal to buy 20 mn Covaxin vaccine doses

Brazil's federal prosecutor's office is investigating possible irregularities in a Health Ministry contract to purchase 20 million doses of the Covaxin vaccine manufactured by Bharat Biotech

Top headlines: Auto,IT lead advance tax payment; Covaxin shows 77% efficacy

Strap: Business Standard brings you the top headlines on Wednesday

Bharat Biotech's Covaxin shows over 77% efficacy in phase 3 trials

The vaccine has shown an efficacy rate of 93 per cent against severe disease and 60 per cent against asymptomatic Covid-19

Bharat Biotech, Pfizer in race for paediatric Covid-19 vax by December

Covaxin in trials already, Serum slated to start testing Novavax by July

Bharat Biotech's pre-submission meeting for Covaxin EUL with WHO on June 23

This comes as a major boost for Bharat Biotech

Best of BS Opinion: Opportunities galore in the east, Covid crisis & more

Here are the best of Business Standard's opinion pieces for Thursday

Covid-19 vaccine pricing accounts for last-mile delivery, say firms

The cost of logistics is built into the final price of the vaccine, especially when supplying to the private sector

Covaxin's final product has no calf serum, Bharat Biotech and govt clarify

Health ministry says this has been used for decades in Polio, Rabies, and Influenza vaccines, is neither used in growth of SARS CoV2 virus nor in the final formulation

Sustainable pricing

Govt and vaccine makers should be transparent

Calf serum used in manufacturing of viral vaccines: Bharat Biotech

However, the final formulation of its Covid-19 vaccine Covaxin is free from all impurities, the firm said

Ocugen selects Jubilant HollisterStier as manufacturer for Covaxin in US

Bharat Biotech's US and Canada partner for Covaxin, said it has chosen Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for the vaccine for the North American countries

Covid-19 vaccine Covaxin at Rs 150 not sustainable: Bharat Biotech

Higher price in private market required to offset part of the costs, argues firm

Bharat Biotech says higher pricing of Covaxin required in private markets

Fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins among few others contribute to higher pricing of Covaxin, Bharat Biotech said

India Coronavirus Dispatch: Lowest daily jump in cases since March 31

New Covid strain on world radar stems from Delta variant, Covaxin is world's third costliest jab and more-news relevant to India's fight against the pandemic